Guideline Recommendations for Continuation of Vortioxetine in Treatment‑Resistant Depression

Definition and Criteria for Treatment‑Resistant Depression

The consensus definition of treatment‑resistant depression (TRD) requires failure of at least two antidepressants with different mechanisms of action, each given at adequate doses for ≥ 4 weeks. [Molecular Psychiatry, 2022] 1
A patient who has documented failure of five distinct antidepressant agents (including SSRIs, atypical antidepressants, and atypical antipsychotic augmentation) meets the TRD criteria, exceeding the minimum threshold. [Molecular Psychiatry, 2022] 1

The American College of Physicians recommends that, when multiple agents show comparable efficacy, clinicians should select a second‑generation antidepressant based on adverse‑effect profile, cost, and patient preferences. [Annals of Internal Medicine, 2016] 2

For patients who achieve a satisfactory response, the American College of Physicians strongly recommends continuing the antidepressant for 4–9 months after the initial response, with an even longer duration for those with recurrent depression. [Annals of Internal Medicine, 2008] 3
Continuing a medication that has demonstrated clinical effectiveness after multiple prior failures (e.g., vortioxetine) is considered an evidence‑based approach under the same ACP guidance. [Annals of Internal Medicine, 2008] 3

The American College of Physicians advises that therapeutic response and adverse effects should be assessed regularly, beginning within 1–2 weeks of any treatment modification. [Annals of Internal Medicine, 2008] 3

In a patient with established clinical stability on vortioxetine (e.g., sustained symptom improvement over several months), the guideline‑based recommendation is to maintain the current dose rather than discontinue or reduce therapy, to avoid relapse. [Annals of Internal Medicine, 2008] 3

Moderate-quality evidence demonstrates that second-generation antidepressants, including vortioxetine, show similar efficacy to cognitive behavioral therapy and other treatment modalities for MDD, with no established superiority of one second-generation antidepressant over another in terms of response or remission rates, according to the American College of Physicians 4, 5, 6, 7, 8

The evidence does not establish superiority of one second-generation antidepressant over another in terms of response or remission rates, suggesting that the choice of antidepressant should be guided by discussion of adverse effects, cost, and patient preferences 8

For patients with first episode major depressive disorder, continue treatment for 4-9 months after satisfactory response, as recommended by the Praxis Medical Insights 9
For patients with recurrent depression, longer duration therapy is beneficial, as recommended by the Praxis Medical Insights 9

The American College of Physicians recommends discussing treatment effects, adverse effect profiles, cost, accessibility, and patient preferences when selecting any second-generation antidepressant, including vortioxetine, as they are generally equally effective for treating major depressive disorder 10, 11